查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493358

美国自体免疫疾病诊断市场规模、份额、趋势分析报告：按类型、测试类型、最终用途、细分市场预测，2024-2030 年

U.S. Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Test Type, By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

美国自体免疫疾病诊断市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国自体免疫疾病诊断市场规模预计将达到30.1亿美元，2024年至2030年复合年增长率为5.2%。

自体免疫疾病盛行率的上升以及诊断工具和技术的不断进步正在显着推动市场的成长。

医疗保健专业人员和患者对自体免疫疾病的认识不断提高，导致诊断和筛检率提高。公共卫生工作、教育宣传活动和宣传工作提高了人们对自体免疫疾病征兆和症状的认识，促使更多的人寻求早期诊断和治疗。针对高风险族群的筛检计画也有助于早期发现自体免疫疾病。

全球医疗保健支出的不断增长以及自体免疫疾病对医疗保健系统带来的日益沉重的负担正在推动对先进诊断解决方案的需求。政府和私人组织正在投资医疗基础设施和研发，以应对自体免疫疾病带来的挑战。这项投资将促进诊断技术的创新，并增加自体免疫疾病患者获得优质诊断服务的机会。

美国自体免疫疾病诊断市场报告亮点

  • 随着超音波、MRI 和 PET 扫描等先进影像技术的兴起，可以对受影响的组织和器官进行详细可视化，局部自体免疫疾病诊断类型在 2023 年以 66.0% 的份额占据市场主导地位。
  • 抗核抗体测试类型将在 2023 年占据最大的市场占有率，并预计在预测期内增长最快。
  • 由于对准确和精确的检测方法的需求不断增长，医院最终用途细分市场将在 2023 年占据市场主导地位。
  • 2023 年 11 月，Progentec Diagnostics 和 Mayo Clinic Laboratories 宣布建立策略伙伴关係，将 Progentec 的取得专利的标记血液检测专利套件商业化，用于自体免疫疾病的早期检测和治疗。该合作伙伴关係旨在改善美国和多个国际市场的患者和临床医生的可及性。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国自体免疫疾病诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国自体免疫疾病诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国自体免疫疾病诊断市场：类型估计与趋势分析

  • 2023 年和 2030 年按类型分類的市场占有率
  • 细分仪表板
  • 美国自体免疫疾病诊断市场按类型前景
  • 2018-2030年市场规模、预测及趋势分析
  • 自体免疫疾病诊断
  • 局部自体免疫疾病诊断

第五章美国自体免疫疾病诊断市场：测试类型估计与趋势分析

  • 2023 年和 2030 年测试类型市场占有率
  • 细分仪表板
  • 按测试类型分類的美国自体免疫疾病诊断市场前景
  • 2018-2030年市场规模、预测及趋势分析
  • 抗核抗体测试
  • 自体抗体测试
  • C反应蛋白
  • 血液常规检查
  • 尿液检查
  • 其他的

第六章美国自体免疫疾病诊断市场：最终用途估计与趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 美国自体免疫疾病诊断市场的最终用途展望
  • 2018-2030年市场规模、预测及趋势分析
  • 医院
  • 诊断中心
  • 其他的

第七章美国自体免疫疾病诊断市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区分類的市场占有率份额
  • 美国自体免疫疾病诊断市场的区域展望
  • 2018-2030年市场规模、预测及趋势分析
  • 西
  • 中西部
  • 东北
  • 西南
  • 东南

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Medtronic
    • Boston Scientific Corporation
    • Johnson &Johnson Service Inc.（Ethicon, Inc.）
    • AngioDynamics
    • Bioventus Inc.（Misonix Inc.）
    • EDAP TMS
    • Chongqing Haifu Medical Technology Co., Ltd
    • Mermaid Medical
    • HealthTronics, Inc.
    • HS Hospital Service SpA
Product Code: GVR-4-68040-285-3

U.S. Autoimmune Disease Diagnostics Market Growth & Trends:

The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques are significantly driving the growth of the market.

Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.

The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.

U.S. Autoimmune Disease Diagnostics Market Report Highlights:

  • Localized autoimmune disease diagnostics type dominated the market with a 66.0% share in 2023 owing to the rising advanced imaging techniques, such as ultrasound, MRI, and PET scans, which allow for detailed visualization of affected tissues or organs.
  • The antinuclear antibody test type segment held the largest market share in 2023 and is anticipated to witness the fastest growth over the forecast period.
  • The hospitals end-use segment dominated the market in 2023 owing to the growing need for accurate and precise testing methods.
  • In November 2023, Progentec Diagnostics and Mayo Clinic Laboratories announced a strategic partnership to commercialize Progentec's range of patented biomarker blood tests for the early detection and treatment of autoimmune disorders. The partnership seeks to improve accessibility for patients and clinicians in the United States and a few international markets.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Test Type
    • 1.2.3. End-use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. Test type outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Autoimmune Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Presence of research funding programs
      • 3.2.1.2. Presence of favorable government initiatives
      • 3.2.1.3. Growing patient awareness levels
      • 3.2.1.4. Technological innovation in the form of lab automation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled
  • 3.3. U.S. Autoimmune Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Autoimmune Disease Diagnostics Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. U.S. Autoimmune Disease Diagnostics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Rheumatoid arthritis
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ankylosing spondylitis diagnostics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Systemic lupus erythematosus (SLE)
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Localized autoimmune disease diagnostics
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Multiple sclerosis
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Type 1 diabetes
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.4. Hashimoto's Thyroiditis
      • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.5. Idiopathic thrombocytopenic purpura
      • 4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.6. Others
      • 4.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis

  • 5.1. Test Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Autoimmune Disease Diagnostics Market by Test Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Antinuclear antibody tests
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Autoantibody tests
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. C-reactive Protein (CRP)
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Complete blood count (CBC)
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Urinalysis
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Autoimmune Disease Diagnostics Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Autoimmune Disease Diagnostics Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Hospitals
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Diagnostic centers
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Autoimmune Disease Diagnostics Market: Region Estimates & Trend Analysis

  • 7.1. Regional Market Share, 2023 & 2030
  • 7.2. U.S. Autoimmune Disease Diagnostics Market by Region Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.3.1. West
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Midwest
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Northeast
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Southwest
      • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.5. Southeast
      • 7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Medtronic
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. AngioDynamics
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Bioventus Inc. (Misonix Inc.)
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. EDAP TMS
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Chongqing Haifu Medical Technology Co., Ltd
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Mermaid Medical
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. HealthTronics, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. H.S. Hospital Service S.p.A.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. autoimmune disease diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 U.S. systemic autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 U.S. localized autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. autoimmune disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. autoimmune disease diagnostics market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. Autoimmune disease diagnostics market: market outlook
  • Fig. 9 U.S. Autoimmune disease diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. Autoimmune disease diagnostics market driver impact
  • Fig. 14 U.S. Autoimmune disease diagnostics market restraint impact
  • Fig. 15 U.S. Autoimmune disease diagnostics market: Type movement analysis
  • Fig. 16 U.S. Autoimmune disease diagnostics market: Type outlook and key takeaways
  • Fig. 17 Systemic autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Ankylosing spondylitis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Systemic lupus erythematosus (SLE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Localized autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Multiple sclerosis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Type 1 diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hashimoto's Thyroiditis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Idiopathic thrombocytopenic purpura market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Autoimmune disease diagnostics Market: Treatment movement Analysis
  • Fig. 29 U.S. Autoimmune disease diagnostics market: Treatment outlook and key takeaways
  • Fig. 30 Surgical ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Percutaneous ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Laparoscopic ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Autoimmune disease diagnostics market: application movement analysis
  • Fig. 34 U.S. Autoimmune disease diagnostics market: application outlook and key takeaways
  • Fig. 35 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. Autoimmune disease diagnostics market: regional movement analysis
  • Fig. 42 U.S. Autoimmune disease diagnostics market: regional outlook and key takeaways
  • Fig. 43 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)